Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

PURPOSE: The combination of lenalidomide, bortezomib, and dexamethasone (RVD) is a highly effective and convenient induction regimen for both transplantation-eligible and -ineligible patients with myeloma. Here, we present the largest cohort of patients consecutively treated with RVD induction thera...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Joseph, Nisha S., Kaufman, Jonathan L., Dhodapkar, Madhav V., Hofmeister, Craig C., Almaula, Dhwani K., Heffner, Leonard T., Gupta, Vikas A., Boise, Lawrence H., Lonial, Sagar, Nooka, Ajay K.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2020
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7587409/
https://ncbi.nlm.nih.gov/pubmed/32298201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02515
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires